Kesimpta (ofatumumab) is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.
Kesimpta is a disease-modifying drug that works by targeting and reducing the number of B-cells in the body. B-cells are a type of white blood cell that can contribute to the inflammation and damage that occur in MS. By reducing the number of B-cells, Kesimpta helps to slow the progression of MS and reduce the frequency and severity of relapses.
Here are some of the key features of Kesimpta:
- Convenient: Kesimpta is the only B-cell treatment for relapsing MS that you can take yourself, once a month, at home or on the go.
- Effective: Kesimpta has been shown to be effective in reducing the number of relapses, slowing the progression of disability, and reducing the number of brain lesions seen on MRI scans.
- Long-term Benefits: Studies have shown that Kesimpta can provide substantial benefits for up to six years, including fewer relapses, reduced MRI lesion activity, and fewer new or enlarging T2 lesions.
Common side effects of Kesimpta:
- Mild infections, such as urinary tract infections (UTIs)
- Reactions at the injection site, such as pain, itching, redness, or other color changes.
Remember: Kesimpta is a prescription medication and should only be taken under the guidance of a healthcare professional.
